Compare BLDR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | BLTE |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 2005 | 2021 |
| Metric | BLDR | BLTE |
|---|---|---|
| Price | $59.04 | $178.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | $121.76 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.9M | 198.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $0.71 | N/A |
| Revenue Next Year | $4.52 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.19 | $65.00 |
| 52 Week High | $145.68 | $200.00 |
| Indicator | BLDR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 58.07 |
| Support Level | N/A | $147.34 |
| Resistance Level | $76.36 | $182.61 |
| Average True Range (ATR) | 2.54 | 7.82 |
| MACD | -0.65 | 2.45 |
| Stochastic Oscillator | 1.94 | 57.31 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.